Biodesix's GeneStrat Includes ROS1 and RET Mutations

Biodesix has broadened its GeneStrat liquid biopsy test to include ROS1 and RET mutations in addition to EGFR sensitizing, EGFR resistance, KRAS, BRAF, and EML4-ALK alterations.

GeneStrat is a part of the Biodesix's larger "Lung Reflex" multi-omic liquid biopsy testing strategy, which also includes the VeriStrat proteomic testing. With results available within 72 hours, the company says that GeneStrat and VeriStrat together deliver comprehensive information for physicians to support critical treatment decisions at initial diagnosis, expediting appropriate treatment.